Profile data is unavailable for this security.
About the company
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its in-house development programs include AT278, Oral GLP-1 and AT247. AT278 is its ultra-concentrated, ultra-rapid acting insulin candidate. AT278 is designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). AT247 is designed to accelerate the absorption of insulin post injection. It is focused on the development of an oral GLP-1 receptor agonist (semaglutide). It has partnered with TRx Biosciences, combining its Arestat technology and TRx Biosciences' lipid technology, Lipicore, to target improved bioavailability of an oral GLP-1 receptor agonist. Its partnered programs include AT220, AT292 and AT351.
- Revenue in GBP (TTM)5.06m
- Net income in GBP-8.10m
- Incorporated2021
- Employees37.00
- LocationArecor Therapeutics PLCChesterford Research ParkLittle ChesterfordSAFFRON WALDEN CB10 1XLUnited KingdomGBR
- Phone+44 122 342 6060
- Websitehttps://arecor.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 6.14m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 7.41m | 12.00 | -- | 1.27 | -- | 0.9351 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 7.90m | 5.00 | -- | 0.9385 | 564.46 | 6.87 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| IXICO PLC | 6.53m | -1.65m | 9.50m | 79.00 | -- | 0.8093 | -- | 1.45 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 10.86m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 16.34m | -- | -- | 2.04 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 19.07m | 24.00 | -- | 23.87 | -- | 11.95 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 23.47m | 5.00 | -- | 10.04 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Arecor Therapeutics PLC | 5.06m | -8.10m | 29.26m | 37.00 | -- | 10.25 | -- | 5.78 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 30.68m | 10.00 | -- | 2.57 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 32.73m | 6.00 | -- | 96.62 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| hVIVO PLC | 51.28m | 5.28m | 41.91m | 301.00 | 7.93 | 0.9606 | 4.68 | 0.8173 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Holder | Shares | % Held |
|---|---|---|
| BGF Investment Management Ltd.as of 07 Jun 2024 | 3.76m | 9.96% |
| Lombard Odier Asset Management (Europe) Ltd.as of 07 Jun 2024 | 1.94m | 5.15% |
| Chelverton Asset Management Ltd.as of 07 Jun 2024 | 1.42m | 3.77% |
| Unicorn Asset Management Ltd.as of 07 Jun 2024 | 1.20m | 3.17% |
| Foresight Group LLP (Investment Management)as of 31 Mar 2025 | 1.12m | 2.97% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2025 | 628.90k | 1.67% |
| Oberon Investments Ltd. (GB Investment Management)as of 31 Mar 2025 | 389.90k | 1.03% |
